Brenus Pharma

Develops next-generation allogeneic immunotherapies to prevent cancer recurrence, the main challenge in solid tumors. The patented technology platform enables the design of first-in-class therapeutic vaccines targeting tumor antigens and training the immune system to overcome tumor resistance. The lead candidate is a proteomic immunotherapy targeting colorectal cancer, the second leading cause of cancer-related death worldwide.